Relieves anxiety and tension associated with psychoneurosis. ANDA 40805, held by Hetero Labs Ltd Iii. Hydroxyzine Hydrochloride.
As of Nov 15, 2026, ANDA 40805 (Hydroxyzine Hydrochloride), held by Hetero Labs Ltd Iii, was first approved by FDA on May 29, 2008, with 3 approved supplements and 0 published complete response letters.
INDICATIONS & USAGE For symptomatic relief of anxiety and tension associated with psychoneurosis and as an adjunct in organic disease states in which anxiety is manifested. Useful in the management of pruritus due to allergic conditions such as chronic urticaria and atopic and contact dermatoses and in histamine-mediated pruritus. As a sedative when used as a premedication and following general anesthesia, hydroxyzine may potentiate meperidine and barbiturates, so their use in pre-anesthetic adjunctive therapy should be modified on an individual basis. Atropine and other belladonna alkaloids are not affected by the drug.
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 29, 2008 | Original application | Approved |
| Hydroxyzine Hydrochloride10MG · tablet;oral | Hydroxyzine Hydrochloride | Rx |
| Hydroxyzine Hydrochloride25MG · tablet;oral | Hydroxyzine Hydrochloride | Rx |
| Hydroxyzine Hydrochloride50MG · tablet;oral | Hydroxyzine Hydrochloride | Rx |
| Sep 26, 2017 | Supplement 3Labeling · Standard review | Approved | None posted |
| Mar 30, 2016 | Supplement 2Labeling · Standard review | Approved | None posted |
| Sep 25, 2014 | Supplement 1Labeling · Standard review | Approved | None posted |
| May 29, 2008 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
